Early-onset hypertension and sex-specific residual risk for cardiovascular disease in type 2 diabetes
Ji H, Ebinger JE, Kwan AC, et al.
Diabetes Care. Pub. Online 24 Apr 2024.
Leggi
Long-term assessment of the NHS hybrid closed-loop real-world study on glycaemic outcomes, time-in-range, and quality of life in children and young people with type 1 diabetes
Ng SM, Wright NP, Yardley D, et al.
BMC Med. Pub. Online 24 Apr 2024.
Leggi
Preoperative GLP-1 receptor agonist use and risk of postoperative respiratory complications
Dixit AA, Bateman BT, Hawn MT, et al.
JAMA. Pub. Online 22 Apr 2024.
Leggi
Effect of 5:2 regimens: energy-restricted diet or low-volume high-intensity interval training combined with resistance exercise on glycemic control and cardiometabolic health in adults with overweight/obesity and type 2 diabetes—a three-arm randomized controlled trial
Li M, Li J, Xu Y, et al.
Diabetes Care. Pub. Online 18 Apr 2024.
Leggi
Could glp-1 receptor agonists like semaglutide treat addiction, Alzheimer disease, and other conditions?
Rubin R
JAMA. Pub. Online 19 Apr 2024.
Leggi
Comparison between a tubeless, on-body automated insulin delivery system and a tubeless, on-body sensor-augmented pump in type 1 diabetes: a multicentre randomised controlled trial
Kim JY, Jin SM, Kang ES, et al.
Diabetologia. Pub. Online 18 Apr 2024.
Leggi
Continuous glucose monitoring with structured education in adults with type 2 diabetes managed by multiple daily insulin injections: a multicentre randomised controlled trial
Kim JY, Jin SM, Sim KH, et al.
Diabetologia. Pub. Online 19 Apr 2024.
Leggi
Undiagnosed type 2 diabetes is common – intensified screening of established risk groups is imperative in Sweden: the SDPP cohort
Gudjonsdottir H, Tynelius P, Stattin NS, et al.
BMC Med. Pub. Online 19 Apr 2024.
Leggi
Kidney and cardiovascular effectiveness of empagliflozin compared to dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes
Edmonston D, Mulder H, Lydon E, et al.
Am J Cardiol. Pub. Online 17 Apr 2024.
Leggi
Glucagon-like peptide-1 receptor agonists use and associations with outcomes in heart failure and type 2 diabetes. Data from the Swedish Heart Failure and Swedish National Diabetes Registries
Wallner M, Biber ME, Stolfo D, et al.
Eur Heart J Cardiovasc Pharmacother. Pub. Online 17 Apr 2024.
Leggi